11/6/2009

Belgian biotech firm ThromboGenics finished enrolling patients in a U.S. Phase III trial of microplasmin, its candidate for back-of-the-eye disease. The company also concluded patient recruitment for a Phase II trial of TB-402, an experimental anti-clotting drug co-developed with Swedish firm BioInvent.

Full Story:
Reuters

Related Summaries